Orchestra BioMed Holdings, Inc. (OBIO) stock
OBIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$7.25+1.10 (+17.89%)
Close on Nov 13, 2026Market cap $435.76MP/E –Yield –
Orchestra BioMed profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Orchestra BioMed's profit margin for the twelve months ending Sep 30, 2026 was -182.5%. For fiscal 2025 it was -157.4%, against -2313.3% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -157.4% | +2155.9 |
| FY2024 | Dec 31, 2024 | -2313.3% | −533.6 |
| FY2023 | Dec 31, 2023 | -1779.7% | −828.5 |
| FY2022 | Dec 31, 2022 | -951.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -20604.4% | −18185.3 |
| Q2 FY2026 | Jun 30, 2026 | -26994.3% | −24678.2 |
| Q1 FY2026 | Mar 31, 2026 | -18810.0% | −16649.3 |
| Q4 FY2025 | Dec 31, 2025 | 20.2% | +6405.6 |
| Q3 FY2025 | Sep 30, 2025 | -2419.0% | −856.1 |
| Q2 FY2025 | Jun 30, 2025 | -2316.1% | −262.2 |
| Q1 FY2025 | Mar 31, 2025 | -2160.7% | +10.7 |
| Q4 FY2024 | Dec 31, 2024 | -6385.4% | −1493.0 |
| Q3 FY2024 | Sep 30, 2024 | -1562.9% | +1615.1 |
| Q2 FY2024 | Jun 30, 2024 | -2054.0% | −737.5 |
| Q1 FY2024 | Mar 31, 2024 | -2171.5% | −1231.6 |
| Q4 FY2023 | Dec 31, 2023 | -4892.4% | −4008.4 |
| Q3 FY2023 | Sep 30, 2023 | -3178.0% | −2294.0 |
| Q2 FY2023 | Jun 30, 2023 | -1316.5% | +640.4 |
| Q1 FY2023 | Mar 31, 2023 | -939.9% | −278.3 |
| Q4 FY2022 | Dec 31, 2022 | -884.0% | – |
| Q3 FY2022 | Sep 30, 2022 | -884.1% | – |
| Q2 FY2022 | Jun 30, 2022 | -1956.9% | – |
| Q1 FY2022 | Mar 31, 2022 | -661.5% | – |
See a number that looks wrong?